X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (122) 122
female (86) 86
male (85) 85
adult (75) 75
hematology (72) 72
middle aged (67) 67
index medicus (53) 53
transplantation (51) 51
adolescent (44) 44
transplantation, homologous (41) 41
oncology (38) 38
bone-marrow-transplantation (35) 35
immunology (31) 31
aged (30) 30
leukemia (29) 29
animals (28) 28
hematopoietic stem cell transplantation (28) 28
treatment outcome (27) 27
chronic myelogenous leukemia (26) 26
stem cell transplantation (24) 24
stem cells (23) 23
chronic myeloid-leukemia (21) 21
retrospective studies (20) 20
therapy (19) 19
versus-host-disease (19) 19
immunotherapy (18) 18
t-lymphocytes - immunology (18) 18
acute myeloid-leukemia (17) 17
bone marrow (17) 17
bone marrow transplantation (17) 17
young adult (17) 17
dendritic cells (16) 16
hematopoietic stem cells (16) 16
risk factors (16) 16
survival (16) 16
versus-host disease (16) 16
survival analysis (15) 15
antineoplastic combined chemotherapy protocols - therapeutic use (14) 14
chemotherapy (14) 14
child (14) 14
dogs (14) 14
leukemia - therapy (14) 14
leukemia, myeloid, acute - therapy (14) 14
prognosis (14) 14
stem-cell transplantation (14) 14
transplantation conditioning (14) 14
acute disease (13) 13
acute myeloid leukemia (13) 13
bone-marrow transplantation (13) 13
cancer (13) 13
flow cytometry (13) 13
follow-up studies (13) 13
hematopoietic stem cell transplantation - adverse effects (13) 13
leukemia, myeloid, acute - immunology (13) 13
prospective studies (13) 13
acute lymphoblastic-leukemia (12) 12
dendritic cells - immunology (12) 12
graft vs host disease - immunology (12) 12
medicine, research & experimental (12) 12
recurrence (12) 12
adoptive immunotherapy (11) 11
cells, cultured (11) 11
graft vs host disease - prevention & control (11) 11
hematopoietic stem cell transplantation - methods (11) 11
remission induction (11) 11
time factors (11) 11
bone marrow transplantation - adverse effects (10) 10
cell biology (10) 10
graft (10) 10
medicine & public health (10) 10
myelodysplastic syndrome (10) 10
donor lymphocyte infusion (9) 9
graft-versus-host disease (9) 9
imatinib mesylate (9) 9
immunophenotyping (9) 9
leukemia, myelogenous, chronic, bcr-abl positive - therapy (9) 9
lymphocyte activation (9) 9
lymphocyte transfusion (9) 9
mortality (9) 9
relapse (9) 9
research (9) 9
t cells (9) 9
t-cells (9) 9
total-body irradiation (9) 9
transplants & implants (9) 9
acute myelogenous leukemia (8) 8
allogeneic stem cell transplantation (8) 8
analysis (8) 8
combined modality therapy (8) 8
differentiation (8) 8
disease-free survival (8) 8
lymphoma (8) 8
bone marrow transplantation - immunology (7) 7
care and treatment (7) 7
cohort studies (7) 7
complications (7) 7
cytotoxicity, immunologic (7) 7
graft vs host disease (7) 7
graft vs host disease - diagnosis (7) 7
graft vs host disease - etiology (7) 7
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2014, Volume 32, Issue 5, pp. 415 - 423
Purpose Deep molecular response (MR4.5) defines a subgroup of patients with chronic myeloid leukemia (CML) who may stay in unmaintained remission after... 
MESYLATE | INTERFERON-ALPHA | THERAPY | CHRONIC-PHASE | ONCOLOGY | RECOMMENDATIONS | CLINICAL-TRIALS | 800 MG | END-POINTS | EUROPEAN-LEUKEMIANET | CHRONIC MYELOID-LEUKEMIA | Piperazines - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Young Adult | Benzamides - administration & dosage | Time Factors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Aged, 80 and over | Adult | Female | Benzamides - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Pyrimidines - administration & dosage | Risk Factors | Proportional Hazards Models | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Disease Progression | Interferon-alpha - administration & dosage | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Fusion Proteins, bcr-abl - metabolism
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2009, Volume 10, Issue 9, pp. 855 - 864
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 22, pp. 3556 - 3557
In this issue of Blood, Leveson-Gower et al describe an immunomodulatory role of mast cells in graft-versus-host-disease (GVHD). 
HEMATOLOGY | Mast Cells - immunology | Animals | Female | Graft vs Host Disease - prevention & control | Male | Graft vs Host Disease - immunology | T-Lymphocytes, Regulatory - immunology
Journal Article
Journal Article
Blood, ISSN 0006-4971, 06/2011, Volume 117, Issue 23, pp. 6375 - 6382
Journal Article
Blood, ISSN 0006-4971, 04/2010, Volume 115, Issue 14, pp. 2960 - 2970
Journal Article